Table 3.

Patient outcomes

Outcome	No. of patients = 111
Posttransplant admission within 100 days, n (%)	30 (27.0)
Posttransplant admission diagnosis, n (%)
Febrile, nonneutropenic	11 (36.7)
Febrile neutropenia	8 (26.7)
Cyclosporine toxicity	5 (16.7)
Other*	6 (20.0)
Posttransplant admission duration, median days (range)	3.5 (1-21)
Cause of death, n (%)	44 (39.6)
Disease progression
Relapse	25 (56.8)
cGVHD	2 (4.5)
aGVHD	1 (2.3)
Cyclosporine microangiopathy	1 (2.3)
Infection (bacterial line infection)	1 (2.3)
Cardiac disease	1 (2.3)
Cerebrovascular accident	1 (2.3)
Patient characteristics at last follow-up, n (%)
Alive	67 (60.4)
Duration of follow-up
1-3 y	40 (59.7)
> 3 y	27 (40.3)
Karnofsky performance status
100%	46 (68.7)
90%	16 (23.9)
80%	4 (6.0)
70%	1 (1.5)
Immunosuppression, number of medications
No immunosuppression	46 (68.7)
1 medication	13 (19.4)
2 medications	5 (7.5)
3 medications	3 (4.5)
Alive, relapse or disease progression	20 (29.9)
Disease-free interval, median days (range)	670 (17-2239)
Current disease status
CR	13 (65.0)
PR	6 (30.0)
PD	2 (10.0)

CR indicates complete remission; PR, partial remission; and PD, progressive disease.

^*CMV enteritis, n = 1; arrhythmia, n = 1; chest pain, n = 1; acute GVHD, n = 1; GI bleed, n = 1; RSV infection, n = 1.